[A13-18] Addendum to Commission A12-18 (dapagliflozin)
Last updated 06.06.2013
Project no.:
A13-18
Commission:
Commission awarded on 23.04.2013 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-53 | Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A12-18 | Dapagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2013-06-06 A G-BA decision was published.